HOBOKEN, NJ — Legacy, a leader in at-home male fertility solutions, announces a significant milestone: the cryogenic preservation of over one trillion sperm. This achievement coincides with the opening of their new state-of-the-art andrology lab in Hoboken, New Jersey.
Paul Simon, VP of Operations at Legacy, highlighted the company’s success in processing approximately 40,000 sperm vials, amounting to about 1.26 trillion spermatozoa. This breakthrough underlines Legacy’s commitment to expanding its facilities and enhancing its services.
Unika Alexander, Manager of R&D Operations, emphasized the meticulous work and precision involved in launching a high-complexity laboratory. The new Hoboken lab, designed and built to be best in class, features custom Standard Operating Protocols (SOPs) and a team of skilled technicians.
Khaled Kteily, Legacy’s founder and CEO, remarked that reaching the one trillion sperm mark signifies not just a numerical achievement but also represents the company’s rapid growth and ambitious vision. The Hoboken lab’s inauguration sets a new benchmark in male fertility care.
Legacy operates as an in-network solution with major insurance providers like Aetna, Cigna, UnitedHealthcare, and collaborates with leading fertility benefit programs such as Carrot, Progyny, Maven, and WINFertility. The company’s dedication to operational excellence is evident through its contributions to research publications and partnerships with prestigious institutions like Harvard University.
Legacy’s innovative model allows clients to access a variety of services from home, including semen analysis, DNA fragmentation analysis, STI testing, and sperm cryopreservation. Unique to Legacy is their post-thaw analysis to ensure sperm viability and multi-site storage for enhanced sample security. This approach offers clients a convenient and comprehensive solution for male fertility needs.